Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how - 26 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- 3Incredible Travel Objections for Craftsmanship Darlings to Visit
- 4There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?
- 5Best bar-b-que Style: Which One Is Your Number one?
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- The most effective method to Decisively Use Open Record Rewards
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- Bombardier Global 8000 Enters Service
- Which European palace do you fantasy about visiting? Vote!
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Figure out How to Establish a long term connection with Your Handshake
- Discovery of massive spider's web in Greece reveals unexpected behavior
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
